This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Down syndrome, unspecified21삼염색체증 NOS

Contents and basic classification information
A. Classification codes ICD-10: Q90.9 / Special Copayment Reduction: V159 / Re-approval cycle: 5 years B. Synonyms None
C. Adult onset Recurrence risk of the translocation type cannot be assessed when the karyotype is unconfirmed; Alzheimer disease, hypothyroidism and premature aging are major adult complications
1. History 2. Causes 3. Genetics 4. General epidemiology
5. Pathophysiology 6. Symptoms 7. Signs 8. Screening
9. Diagnosis 10. Treatment 11. Prognosis 12. Prevention
13. References

1. History

ICD-10 Q90.9 "Down syndrome, NOS (Not Otherwise Specified)" is the code applied when the clinical phenotype of Down syndrome is met but cytogenetic karyotyping has not been performed or results were not obtained. The clinical significance of this code is not simply that of a residual classification category; it serves to capture the group of patients in real-world clinical practice who have not reached cytogenetic confirmation.

Historically, after John Langdon Down's clinical description in 1866, Down syndrome was diagnosed for about 90 years by clinical phenotype alone without cytogenetic diagnosis. Even after Lejeune's discovery of trisomy 21 in 1959, cytogenetic testing was not immediately introduced into all health systems, and in resource-limited regions it was not uncommon, even into the 1970s–1980s, for clinical diagnosis to be made without genetic testing.

In the ICD classification system, the Q90.9 code was introduced together with the classification of the genetic subtypes of Down syndrome. The World Health Organization's ICD-10 (published 1992) distinguished Q90.0 (meiotic nondisjunction), Q90.1 (mosaicism), Q90.2 (translocation) and Q90.9 (NOS), which formally recognized the clinical importance of distinguishing cytogenetic subtypes. In practice, however, the pathways to confirming Down syndrome are diverse, and in some low-resource settings or special clinical situations the Q90.9 code is used without karyotype analysis.

Current clinical guidelines recommend cytogenetic karyotype analysis in all cases in which Down syndrome is clinically suspected and emphasize that subtype distinction is essential, particularly for assessing the familial recurrence risk of translocation Down syndrome. Therefore, the Q90.9 code should be used as a provisional diagnosis and then updated to the appropriate subtype code (Q90.0, Q90.1, Q90.2) according to the karyotype result.


2. Causes

The Q90.9 code applies when the clinical diagnosis of Down syndrome has been established but cytogenetic karyotyping is not performed, in progress, or has failed to yield a result. The cause may be any of the three established cytogenetic mechanisms—meiotic nondisjunction, translocation or mosaicism.

Situations in which the Q90.9 code applies

The main situations in which the Q90.9 code is used in clinical practice are as follows. First, it is used as a provisional code during the period after a clinical diagnosis in the neonatal period while karyotype results are still awaited. Second, only a clinical diagnosis has been made because access to cytogenetic testing is limited in developing countries or resource-limited settings. Third, a retrospective clinical diagnosis has been made in a deceased patient but no genetic specimen is available. Fourth, in some existing records, previous karyotype results have been lost or not documented.

Clinically expected distribution of mechanisms

If karyotyping were performed in the patient group classified as Q90.9, statistically about 95% would be expected to have standard trisomy (Q90.0), about 3–4% translocation (Q90.2), and about 1–2% mosaicism (Q90.1). This is an estimate reflecting the overall distribution of Down syndrome types. In particular, the possibility of translocation or mosaicism should be kept in mind when maternal age is young (under 35), family history is positive, or the phenotype is mild.

Limitations of clinical diagnostic criteria

Diagnosing Down syndrome by clinical diagnostic criteria alone is possible, but the Down syndrome phenotype can vary with age, the proportion of mosaicism and individual variation, so the accuracy of clinical diagnosis is limited. In particular, the mosaic type lacks a typical phenotype and is difficult to confirm by clinical diagnosis alone. Therefore, coding as Q90.9 without cytogenetic confirmation should be minimized.


3. Genetics

In Q90.9 the cytogenetic mechanism has not been identified, so the genetic subtype remains undetermined until karyotype analysis. However, after the clinical diagnosis is established, appropriate testing should be performed as soon as possible for genetic confirmation.

Clinical necessity of confirming the cytogenetic subtype

The most important reason to confirm the cytogenetic subtype of Down syndrome is differentiation of the translocation type (Q90.2). In the translocation type, one parent may be a carrier of a balanced Robertsonian translocation, in which case the risk of Down syndrome recurring in subsequent pregnancies rises to 10–15% (maternal carrier) or 2–5% (paternal carrier). Managing as Q90.9 without karyotype analysis misses this information, and the opportunity for prevention in the family's next pregnancy is lost.

Prerequisite for genetic counseling

Genetic counseling should be based on karyotype results. With standard trisomy (Q90.0), the recurrence risk is low at the age-adjusted risk + about 1% additional risk, but with the translocation type (Q90.2), identification of parental carriers and preimplantation genetic testing (PGT-SR) or prenatal diagnosis must be discussed. With the mosaic type (Q90.1), differences in prognosis according to the proportion and tissue distribution of mosaicism must be explained. At the Q90.9 stage, this counseling is necessarily incomplete.

Gene composition of chromosome 21 and the Down syndrome critical region

Regardless of subtype, the Down syndrome phenotype is determined by overexpression of genes in a specific region of the long arm of chromosome 21, particularly the 21q22.13 region. This region is called the Down syndrome critical region (DSCR) and includes genes such as DSCR1 (RCAN1), DYRK1A, KCNJ6 and DSCR3. Overexpression of DYRK1A is involved in abnormal neurodevelopment and intellectual disability, and RCAN1 (DSCR1) inhibits the calcineurin signaling pathway, affecting synaptic plasticity and memory formation.

APP and the association with Alzheimer disease

The APP (amyloid precursor protein) gene on chromosome 21 is expressed at triple dosage, increasing amyloid β production, which causes Alzheimer pathology (amyloid plaques, neurofibrillary tangles) from the 40s. This is the same mechanism by which APP gene duplication causes early-onset familial Alzheimer disease. This association applies to all Down syndrome in which the long arm of chromosome 21 is present in three copies, regardless of subtype.


4. General epidemiology

The proportion in which the Q90.9 code is used varies greatly by health system and region. In high-income countries with high access to cytogenetic testing, most Down syndrome is classified as one of Q90.0, Q90.1 or Q90.2 and Q90.9 is used only as a provisional code, whereas in low-resource settings Q90.9 may account for a relatively high proportion.

Overall epidemiology of Down syndrome

The overall birth frequency of Down syndrome is about 1/700–1/800, and about 200,000 births per year are estimated worldwide. In 2011, the global prevalence of Down syndrome was estimated at about 6 million (based on live-born survivors). In Korea, the number of registered Down syndrome patients in health insurance data is steadily increasing, and tens of thousands are currently receiving care.

Impact of prenatal diagnosis and prenatal intervention

Since NIPT became widespread, the number of Down syndrome births has declined in some high-income countries, but this reflects changes in decisions about continuing pregnancy and is not simply an improvement in prevention rates. In addition, NIPT is a screening test, so clinical processes should be designed so that the error of coding as Q90.9 without confirmation does not occur.

Growth of the adult Down syndrome population

With medical advances, the life expectancy of people with Down syndrome has been greatly extended, and the number of adult patients is rising sharply. In the United States, more than half of the Down syndrome population is now 18 or older, and the number of patients aged 60 or older is also increasing. In adults with Down syndrome, management of Alzheimer disease, thyroid disease, mental health problems and others has emerged as a major clinical challenge. Retrospective karyotype analysis is recommended even in adult patients classified as Q90.9 for the management of these complications.


5. Pathophysiology

Because Q90.9 is a state in which the karyotype is unconfirmed, the pathogenetic mechanism has not been identified. However, since it presents a clinically confirmed Down syndrome phenotype, it is certainly due to one of the three established mechanisms—meiotic nondisjunction, mitotic nondisjunction (mosaicism) or Robertsonian translocation. For a detailed description of each mechanism, refer to the Q90.0, Q90.1 and Q90.2 entries.

Common pathophysiology: gene dosage imbalance of chromosome 21

Regardless of mechanism, the Down syndrome phenotype is explained by triple-dose expression of genes on the long arm of chromosome 21 (gene dosage effect). Expression increased 1.5-fold from the normal two copies disrupts protein interaction networks and developmental signaling pathways as a whole. This quantitative change has wide-ranging effects on brain development, heart formation, immune function, hematopoiesis, endocrine regulation and more, producing the multisystem phenotype of Down syndrome.

Mechanism of neurodevelopmental abnormalities

Overexpression of DYRK1A alters cell cycle regulation of neural progenitor cells, reducing the number of neurons in the cerebral cortex. Overexpression of RCAN1 (DSCR1) inhibits the activity of the serine/threonine phosphatase calcineurin, impairing activation of the NFAT transcription factor and reducing long-term potentiation (LTP) and memory formation capacity. KCNJ6 (GIRK2) overexpression is associated with abnormal cerebellar development. The combined excess of these genes forms the cell-biological basis of intellectual disability.

Mechanism of congenital heart disease

Overexpression of the COL6A1 and COL6A2 genes (chromosome 21) alters the extracellular matrix composition of the endocardial cushions, promoting formation of atrioventricular septal defects (AVSD). Overexpression of the ERG and ETS2 transcription factors also affects the cardiac morphogenesis gene network. In the developmental mechanism of congenital heart disease, the effects of chromosome 21 gene excess and each patient's own genetic background act in combination.

Mechanism of immune and hematologic abnormalities

The RUNX1 (AML1) transcription factor on chromosome 21 is central to hematopoietic development, and its overexpression causes megakaryoblast proliferation and an increased risk of leukemia. Together with GATA1 gene variants, the risk of transient abnormal myelopoiesis (TAM) and acute megakaryoblastic leukemia (DS-AMKL) increases. Immune dysfunction arises from combined impairment of T-cell development, NK cell function and antibody responses.

Mechanism of Alzheimer pathology

Triple-dose expression of the APP gene increases production of amyloid precursor protein (APP), and cleavage by β-secretase (BACE1) and γ-secretase is promoted, leading to accumulation of amyloid β40 and β42. Amyloid β plaque formation initiates the Alzheimer cascade leading to neuroinflammation, synapse loss and tau protein hyperphosphorylation (neurofibrillary tangle formation). Alzheimer pathology is observed after age 40 in almost all patients with Down syndrome, and the incidence of clinical Alzheimer dementia reaches 50–70% by age 65.


6. Symptoms

Because patients classified as Q90.9 clinically meet the Down syndrome phenotype, their symptoms are the same as the clinical spectrum of Down syndrome as a whole, regardless of cytogenetic subtype.

Neurodevelopment and intellectual disability

Intellectual disability occurs in almost all patients. IQ is mostly in the 40–70 range (mild to moderate), based on standard trisomy. In language development, receptive language is relatively preserved compared with expressive language. Short-term auditory memory, processing speed and sequential information processing are weak, while musical ability and social perception are relative strengths. Seizures, infantile spasms and developmental regression may occur.

Congenital anomalies

Congenital heart disease is present in about 40–50%, with AVSD the most common. Gastrointestinal malformations (duodenal atresia, Hirschsprung disease) occur in about 2–12%, and thyroid malformations and urinary tract malformations are also reported.

Musculoskeletal symptoms

Generalized hypotonia, ligamentous laxity, atlantoaxial instability, flat feet, scoliosis, hip instability and others occur. Hypotonia is the most prominent early finding in the neonatal period and causes feeding difficulties and delayed motor development.

Endocrine and metabolic abnormalities

Hypothyroidism (congenital or autoimmune) is very common, occurring in about 40% by adulthood. Obesity, diabetes and osteoporosis are also major complications in adulthood. In women, early menopause may occur in the 20s–30s.

Immune and hematologic abnormalities

Recurrent infections (respiratory, middle ear, skin), autoimmune diseases (thyroiditis, celiac disease, rheumatic diseases), transient abnormal myelopoiesis (TAM, about 10% of neonates) and an increased risk of leukemia (ALL, AMKL) are characteristic.

Alzheimer disease in adulthood

Alzheimer pathology begins to develop from the 40s, and clinical dementia rises sharply in the 50s–60s. Cognitive decline, memory impairment, behavioral change, increased seizures and decline in daily functioning appear sequentially.


7. Signs

The clinical signs of Down syndrome NOS (Q90.9) are interpreted in the same way as the signs of standard trisomy, keeping in mind that cytogenetic testing to confirm the subtype must be performed concurrently.

Craniofacial signs

Upslanting palpebral fissures are the most characteristic facial sign and a key finding suggesting Down syndrome. Epicanthal folds, Brushfield spots (white spots on the iris), a short flat nose, small low-set ears, a short neck and a flat occiput (brachycephaly) appear in combination. Tongue protrusion (macroglossia or relatively small oral cavity), a narrow palate and dental abnormalities are also commonly observed.

Limb and skin signs

A single palmar crease (simian crease), incurved fifth finger (clinodactyly) and a widened gap between the first and second toes (sandal gap) are characteristic. In dermatoglyphics, an increase in bilateral ulnar loops is reported. Dry skin, seborrheic dermatitis and alopecia areata are common.

Musculoskeletal signs

Generalized hypotonia is prominent in the neonatal period, and hyperextensible joints due to ligamentous laxity and flat feet are observed. With growth, a tendency to obesity appears, and secondary joint problems due to obesity may also occur.

Neurological signs

Deep tendon reflexes may be somewhat reduced, and impaired coordination may occur due to cerebellar dysfunction. After the onset of Alzheimer disease, cognitive decline, reduced verbal fluency, gait disturbance and increased seizure frequency appear as signs.

Ophthalmologic and otolaryngologic signs

Refractive errors (myopia, hyperopia, astigmatism), strabismus, nystagmus, keratoconus and congenital or early-onset cataracts are common. Conductive hearing loss due to recurrent otitis media, or sensorineural hearing loss, may occur. Regular ophthalmologic and hearing evaluations are essential.


8. Screening

Screening in situations where the Q90.9 code applies follows the same framework as overall Down syndrome screening. What matters is to proceed quickly with cytogenetic testing to confirm the subtype even after clinical Down syndrome has been identified.

Prenatal screening

First-trimester combined screening (NT + PAPP-A + free β-hCG), quadruple serum marker screening (AFP, β-hCG, uE3, inhibin A) and NIPT (cell-free fetal DNA analysis) are the main screening tools. NIPT shows high accuracy for trisomy 21, with sensitivity over 99% and specificity over 99.9%, but because it is a screening test, invasive confirmation is needed. After confirmation, karyotype analysis must be performed to determine the subtype.

Newborn screening and clinical diagnosis

If Down syndrome is suspected in the neonatal period from clinical findings (facial phenotype, hypotonia, single palmar crease, etc.), blood is drawn immediately and karyotype analysis is requested. Until karyotype results are available, basic tests including echocardiography proceed, and if necessary a provisional claim is made under the Q90.9 code. After the results are confirmed, the code must be updated to the applicable one of Q90.0, Q90.1 or Q90.2.

Pediatric and adult monitoring

Regular monitoring items after confirmation of Down syndrome are the same regardless of subtype. Thyroid function tests (TSH, free T4) are performed in the neonatal period, at 6 months, at 12 months and annually thereafter. Hearing tests are performed every 6–12 months and ophthalmologic examinations once or twice a year. Cervical spine radiography to assess atlantoaxial instability is performed before high-risk activities. In adulthood, baseline assessment for Alzheimer disease begins at age 30–35 and is followed every 2–3 years thereafter.


9. Diagnosis

In patients assigned the Q90.9 code, the most important next step is confirmation of the subtype by cytogenetic karyotype analysis. This is essential for genetic counseling, recurrence risk assessment and deciding whether to test family members.

Clinical diagnostic criteria

The clinical diagnosis of Down syndrome is based on a combination of findings such as the characteristic facial phenotype (upslanting palpebral fissures, epicanthal folds, Brushfield spots, flat nose, small ears), hypotonia, single palmar crease, intellectual disability and congenital malformations. Clinical diagnosis in the neonatal period is made by an experienced neonatologist or clinical geneticist, and Down syndrome diagnostic scoring systems (e.g., the Aitken criteria) are used as auxiliary tools.

G-banded karyotype analysis and FISH

Karyotype analysis is performed on peripheral blood lymphocytes, skin fibroblasts or prenatal specimens (amniotic fluid, chorionic villus cells). Standard karyotype analysis (20 or more metaphase cells) confirms whether trisomy or translocation is present. When mosaicism is suspected, 50 or more cells are analyzed or FISH is performed concurrently. FISH is useful for producing rapid results but has limitations in fully distinguishing subtypes, so it should be combined with karyotype analysis.

Chromosomal microarray (CMA)

SNP-based microarray can confirm trisomy while also estimating the proportion of mosaicism, identifying UPD and detecting additional chromosomal abnormalities. However, it is limited in detecting balanced translocations, so when the translocation type is suspected, karyotype analysis must be performed concurrently.

Need for parental karyotype analysis

When karyotype analysis confirms the translocation type (Q90.2), parental karyotype analysis must be performed to determine whether a parent is a balanced carrier. Even with standard trisomy (Q90.0), parental karyotypes are reviewed if maternal age is very young or there is a family history. For the mosaic type (Q90.1), multi-tissue analysis is considered.

Prenatal confirmation methods

Prenatal karyotype analysis is performed by CVS (10–13 weeks of gestation) or amniocentesis (15–20 weeks of gestation), and results are usually available within 2–3 weeks. QF-PCR (quantitative fluorescent PCR) is used to rapidly confirm trisomy 21 within a few hours, but karyotype analysis is needed to distinguish subtypes.


10. Treatment

Treatment of patients with Down syndrome managed under the Q90.9 code follows standard Down syndrome clinical management guidelines. Necessary treatment (correction of congenital malformations, thyroid treatment, etc.) should not be delayed even before the subtype is confirmed.

Treatment of congenital heart disease

Echocardiography is performed in the neonatal period to check for cardiac malformations, and when an atrioventricular septal defect (AVSD), ventricular septal defect (VSD) or similar is found, the timing of surgical repair is decided in consultation with pediatric cardiac surgery. As a rule, repair is performed within 3–6 months to prevent a rise in pulmonary vascular resistance. A multidisciplinary team approach involving cardiology, anesthesiology and critical care medicine before surgery is important.

Management of gastrointestinal malformations

Duodenal atresia, esophageal malformations and Hirschsprung disease are surgically corrected early in collaboration with neonatal surgery and pediatric surgery. Gastroesophageal reflux disease is managed with medication and positional therapy. Hirschsprung disease is diagnosed by rectal suction biopsy and surgically corrected (Swenson, Soave, Duhamel procedures, etc.).

Thyroid and endocrine management

When hypothyroidism is diagnosed, it is treated with levothyroxine, with TSH targets set appropriately for age. Nutritional counseling, encouragement of physical activity and behavior modification programs are provided to prevent obesity. Diabetes is controlled with lifestyle management and, if needed, medication.

Neurodevelopmental rehabilitation and early intervention

Early intervention programs—speech therapy (receptive/expressive language, feeding skills), occupational therapy (sensory integration, fine motor), physical therapy (gross motor, postural control)—begin immediately after diagnosis. Support in special education and inclusive education settings has a positive effect on cognitive and functional outcomes. In adulthood, vocational training, support for community living skills and independent living programs are important.

Hematologic and oncologic management

When transient abnormal myelopoiesis (TAM) occurs in the neonatal period, GATA1 variant analysis and follow-up are performed in consultation with a hematologist. When DS-AMKL occurs, it is treated with low-dose cytarabine–based chemotherapy. When ALL occurs, general pediatric ALL treatment protocols are followed, with doses adjusted in view of the increased risk of methotrexate toxicity.

Management of Alzheimer disease

Baseline cognitive assessment begins at age 30–35, followed by neuropsychological and daily functioning assessments every 2–3 years. When Alzheimer disease is clinically diagnosed, acetylcholinesterase inhibitors (donepezil, rivastigmine) are considered, and strengthening of family support and social care is supported. Clinical trials of anti-amyloid antibody therapy are currently under way in Down syndrome cohorts, so participation in such trials can be discussed.


11. Prognosis

Because patients with the Q90.9 code have been clinically confirmed as having Down syndrome, prognosis follows the overall Down syndrome prognostic spectrum. Once the cytogenetic subtype is confirmed, prognostic prediction becomes more accurate.

Life expectancy

With medical advances, average life expectancy has been extended to 60 years or more. Patients whose congenital heart disease was corrected early, whose thyroid function is well managed and in whom recurrent infections are well prevented can expect a longer life span. After the onset of Alzheimer dementia, functional decline and complications such as aspiration pneumonia increase the risk of death.

Cognitive prognosis

Most have moderate intellectual disability at an IQ level of 40–70, but functional level can be maximized with appropriate educational support and early intervention. Some are capable of semi-independent living and supported employment. When cognitive decline due to Alzheimer pathology begins after the 40s, functional level declines rapidly.

Quality of life

The quality of life of people with Down syndrome and their families depends greatly not only on the level of medical management but also on the level of social integration, educational opportunities and community support. Recent studies have confirmed that a substantial proportion of adults with Down syndrome report high levels of life satisfaction.

Prognostic implications of subtype confirmation

When karyotyping in Q90.9 reveals the translocation type (Q90.2), assessing recurrence risk through parental karyotype analysis and supporting appropriate reproductive planning can make a decisive contribution to the family's outlook. Subtype confirmation does not change the clinical prognosis of the individual patient, but it provides key information for family prevention strategies.


12. Prevention

In patients coded as Q90.9, the most important preventive measure is to perform cytogenetic karyotype analysis promptly to rule out the possibility of translocation Down syndrome.

Subtype confirmation and recurrence risk assessment through karyotype analysis

When the translocation type (Q90.2) is confirmed, balanced Robertsonian translocation carriers are identified through parental karyotype analysis, the recurrence risk is accurately calculated, and genetic counseling on planning the next pregnancy is provided. In balanced translocation carriers, recurrence of translocation Down syndrome can be prevented through preimplantation genetic testing (PGT-SR) or prenatal diagnosis (CVS/amniocentesis).

Enhanced prenatal screening

In the next pregnancy, prenatal screening tests (NIPT, first-trimester combined screening) are performed, and for parents who are balanced translocation carriers, CVS or amniocentesis is recommended regardless of the results. If NIPT is positive, invasive confirmatory testing including karyotype analysis must be performed.

Prevention and early detection of complications

After the diagnosis of Down syndrome is established, vaccinations (influenza, pneumococcal, COVID-19, RSV, etc.) are completed, and thyroid function tests, hearing tests, ophthalmologic examinations and atlantoaxial instability assessment are performed regularly. Dietary management and physical activity to prevent obesity are important for preventing metabolic complications. In adulthood, baseline cognitive assessment for Alzheimer screening and subsequent regular follow-up are essential.

Family support and social prevention

Connection to community support services, self-help groups and specialized medical networks for people with Down syndrome and their families is supported. Psychological and practical support to prevent carer burnout contributes to improving the quality of life of both patients and families.


13. References

  1. Lejeune J, Gautier M, Turpin R. Étude des chromosomes somatiques de neuf enfants mongoliens. C R Acad Sci. 1959;248:1721–1722.
  2. Bull MJ; Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2011;128(2):393–406. doi:10.1542/peds.2011-1605
  3. Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM. Down syndrome—recent progress and future prospects. Hum Mol Genet. 2009;18(R1):R75–R83. doi:10.1093/hmg/ddp010
  4. Patterson D. Molecular genetic analysis of Down syndrome. Hum Genet. 2009;126(1):195–214. doi:10.1007/s00439-009-0696-8
  5. Loane M, Morris JK, Addor MC, et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe. Eur J Hum Genet. 2013;21(1):27–33. doi:10.1038/ejhg.2012.94
  6. Malt EA, Dahl RC, Haugsand TM, et al. Health and disease in adults with Down syndrome. Tidsskr Nor Laegeforen. 2013;133(3):290–294. doi:10.4045/tidsskr.12.0390
  7. Hassold T, Hunt P. To err (meiotically) is human: the genesis of human aneuploidy. Nat Rev Genet. 2001;2(4):280–291. doi:10.1038/35066065
  8. Strydom A, Shooshtari S, Lee L, et al. Dementia in older adults with intellectual disabilities. J Policy Pract Intellect Disabil. 2010;7(2):96–110. doi:10.1111/j.1741-1130.2010.00253.x
  9. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005;353(19):2001–2011. doi:10.1056/NEJMoa043693
  10. Antonarakis SE, Skotko BG, Rafii MS, et al. Down syndrome. Nat Rev Dis Primers. 2020;6(1):9. doi:10.1038/s41572-019-0143-7